Modality
Bispecific Ab
MOA
FGFRi
Target
LAG-3
Pathway
Amyloid
TTR Amyloidosis
Development Pipeline
Preclinical
~Jun 2022
→ ~Sep 2023
Phase 1
~Dec 2023
→ ~Mar 2025
Phase 2
Jun 2025
→ May 2025
Phase 2Current
NCT06081825
1,419 pts·TTR Amyloidosis
2025-06→2025-05·Not yet recruiting
1,419 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-05-0611mo agoPh3 Readout· TTR Amyloidosis
Trial Timeline
P2/3
Not yet…
Catalysts
Ph3 Readout
2025-05-06 · 11mo ago
TTR Amyloidosis
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06081825 | Phase 2/3 | TTR Amyloidosis | Not yet recr... | 1419 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 | |
| STO-2663 | Stoke Ther | Approved | LAG-3 |